Intervention

sodium phenylbutyrate

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 4 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials4

Recruiting0

Common conditions10

Lead sponsors shown4

Clinical trials

4 shown

The Effects of Sodium Phenylbutyrate on Circulating Branched Chain Amino AcidsNCT05028803 · 2021-09-01

COMPLETED

Effect of Endoplasmic Reticulum Stress on Metabolic FunctionNCT00771901 · 2008-02-01

COMPLETED

Mechanism of Fatty Acid-induced Impairment of Glucose-simulated Insulin Secretion - Effect of BuphenylNCT00533559 · 2007-09-01

COMPLETED

Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate CancerNCT00006019 · 2000-05-01

COMPLETED

Common conditions

Diabetes2 Insulin Resistance2 Leukemia1 Lung Cancer1 Lymphoma1 Multiple Myeloma and Plasma Cell Neoplasm1 Myelodysplastic Syndromes1 Obese Non Diabetic1 Obesity1 Prostate Cancer1

Leading sponsors

Memorial Sloan Kettering Cancer Center 1 University Health Network, Toronto 1 University of Nottingham 1 Washington University School of Medicine 1

Trial status mix

COMPLETED4

Phase mix

NA2

PHASE21

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.